- Home
- MDB vs IQV Comparison
MDB vs IQV Comparison
Compare MDB & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDB | IQV |
|---|---|---|
| Founded | 2007 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8B | 36.4B |
| IPO Year | 2017 | 2013 |
Fundamental Metrics
Financial Performance| Metric | MDB | IQV |
|---|---|---|
| Price | $429.55 | $221.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 37 | 17 |
| Target Price | ★ $413.25 | $237.59 |
| AVG Volume (30 Days) | ★ 2.3M | 1.4M |
| Earning Date | 12-01-2025 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 7.30 |
| Revenue | $2,317,123,000.00 | ★ $15,904,000,000.00 |
| Revenue This Year | $18.77 | $6.14 |
| Revenue Next Year | $17.04 | $5.35 |
| P/E Ratio | ★ N/A | $30.47 |
| Revenue Growth | ★ 20.93 | 3.85 |
| 52 Week Low | $140.78 | $134.65 |
| 52 Week High | $432.55 | $234.30 |
Technical Indicators
Market Signals| Indicator | MDB | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 68.19 | 47.58 |
| Support Level | $408.00 | $220.12 |
| Resistance Level | $432.55 | $225.80 |
| Average True Range (ATR) | 13.76 | 5.19 |
| MACD | 1.69 | -1.06 |
| Stochastic Oscillator | 90.83 | 35.74 |
Price Performance
Historical ComparisonAbout MDB MongoDB Inc.
Founded in 2007, MongoDB is a vendor of a document-oriented database that accelerates development processes of new applications. Enterprise customers can choose between the fully managed offering, MongoDB Atlas, or the self-managed version, MongoDB Enterprise Advanced. MongoDB is a popular tool among developers, and its free Community Server has recorded over 500 million downloads since 2009.
About IQV IQVIA Holdings Inc.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.